Home » Stocks » BEAM

Beam Therapeutics Inc. (BEAM)

Stock Price: $99.51 USD 6.88 (7.43%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $100.06 +0.55 (0.55%) Jan 22, 7:59 PM
Market Cap 5.81B
Revenue (ttm) 18,000
Net Income (ttm) -131.52M
Shares Out 50.09M
EPS (ttm) -3.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $99.51
Previous Close $92.63
Change ($) 6.88
Change (%) 7.43%
Day's Open 96.00
Day's Range 92.68 - 100.00
Day's Volume 970,894
52-Week Range 13.31 - 113.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 4 days ago

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, inv...

Other stocks mentioned: CRSP, EDIT, NTLA, SWTX
GlobeNewsWire - 4 days ago

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, ...

InvestorPlace - 1 week ago

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...

Other stocks mentioned: CLLS, CLXT, CRSP, EDIT, NTLA, SGMO
GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Zacks Investment Research - 2 weeks ago

Investors need to pay close attention to Beam Therapeutics (BEAM) stock based on the movements in the options market lately.

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

InvestorPlace - 1 month ago

Listen in to hear how you can profit in 2021 and beyond

Other stocks mentioned: ARKG, BEEM, CRSP, EH, F, GIX, LAZR, LI, NIO, OAC, QS, TM, TSLA, VWAGY, XPEV
GuruFocus - 1 month ago

If analysts are even close to being on target, it may be time for early investors to cash in on their shares of Beam Therapeutics Inc. (NASDAQ:BEAM). The stock of the Cambridge, Massachusetts-...

Seeking Alpha - 1 month ago

Beam Therapeutics was co-founded by David Liu, who invented base editing and prime editing technologies for gene editing. David Liu also co-founded Editas.

GlobeNewsWire - 1 month ago

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed ; Will Support Planned IND Submi ssion in the Second Half of 2021

GlobeNewsWire - 2 months ago

Magazine honors company for second year in a row Magazine honors company for second year in a row

GlobeNewsWire - 2 months ago

Novel Base Edit ors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation C orrection than Required to Restore Glucose H omeostasis

GlobeNewsWire - 2 months ago

BEAM -201 , a n Off the Shelf Allogeneic CD7-Targeting CAR-T , Named as Development Candidate for Treatment of T-ALL ; First Cell Therapy Featuring Four Simultaneous Genetic Edits ; Demonstrat...

GlobeNewsWire - 2 months ago

BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Ca ndidate for Treatment of T- Cell Acute Lymphoblastic Leukemia

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced toda...

The Motley Fool - 5 months ago

A rumored merger has investors excited, although details are scarce.

Other stocks mentioned: EDIT
Benzinga - 5 months ago

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher on Wednesday after William Blair initiated coverage on the company's stock with an Outperform rating and announced a $33 price ta...

GlobeNewsWire - 5 months ago

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announ...

GuruFocus - 8 months ago

Shares of a Cambridge, Massachusetts-based biotechnology company that is taking a different approach to gene editing have gained more than 25% since its early February initial public offering.

GlobeNewsWire - 8 months ago

Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo

GlobeNewsWire - 9 months ago

Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs Successful Initial Public Offering Completed and Continued Advancement ...

GlobeNewsWire - 10 months ago

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today annou...

24/7 Wall Street - 10 months ago

Beam Therapeutics Inc. (NASDAQ: BEAM) is not exactly a household name in corporate America.

The Motley Fool - 11 months ago

Beam Therapeutics' new approach offers more precision than CRISPR.

About BEAM

Beam Therapeutics, a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collab... [Read more...]

Industry
Biotechnology
IPO Date
Feb 6, 2020
CEO
John M. Evans M.B.A.
Employees
166
Stock Exchange
NASDAQ
Ticker Symbol
BEAM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is 59.20, which is a decrease of -40.51% from the latest price.

Price Target
$59.20
(-40.51% downside)
Analyst Consensus: Buy